Log in

TransEnterix Stock Price, News & Analysis (NYSEAMERICAN:TRXC)

$0.44
+0.01 (+2.33 %)
(As of 10/18/2019 03:44 AM ET)
Today's Range
$0.42
Now: $0.44
$0.45
50-Day Range N/A
52-Week Range
$0.41
Now: $0.44
$4.80
Volume2.92 million shs
Average Volume2.58 million shs
Market Capitalization$95.81 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$95.81 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.


TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) issued its quarterly earnings data on Wednesday, August, 7th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The medical instruments supplier earned $3.64 million during the quarter, compared to the consensus estimate of $5.13 million. View TransEnterix's Earnings History.

When is TransEnterix's next earnings date?

TransEnterix is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for TransEnterix.

What price target have analysts set for TRXC?

4 Wall Street analysts have issued 1-year price objectives for TransEnterix's shares. Their predictions range from $1.00 to $5.00. On average, they expect TransEnterix's share price to reach $2.65 in the next year. This suggests a possible upside of 502.3% from the stock's current price. View Analyst Price Targets for TransEnterix.

What is the consensus analysts' recommendation for TransEnterix?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransEnterix.

Has TransEnterix been receiving favorable news coverage?

Headlines about TRXC stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransEnterix earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for TransEnterix.

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), NVIDIA (NVDA), Actinium Pharmaceuticals (ATNM), Geron (GERN), Opko Health (OPK) and Sarepta Therapeutics (SRPT).

Who are TransEnterix's key executives?

TransEnterix's management team includes the folowing people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

Who are TransEnterix's major shareholders?

TransEnterix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tradewinds Capital Management LLC (0.04%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Todd Pope and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.

Which major investors are buying TransEnterix stock?

TRXC stock was acquired by a variety of institutional investors in the last quarter, including Tradewinds Capital Management LLC. View Insider Buying and Selling for TransEnterix.

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $0.44.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $95.81 million. View Additional Information About TransEnterix.

What is TransEnterix's official website?

The official website for TransEnterix is http://www.transenterix.com/.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.


MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  416 (Vote Underperform)
Total Votes:  775
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Featured Article: Institutional Investors

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel